| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Assessment of compliance with hormonal therapy in early breast cancer patients with positive hormone receptor phenotype: A single institution study
|
Elsamany, Shereef Ahmed
|
|
|
62 |
C |
p. 69-74
|
article
|
| 2 |
Editorial Board
|
|
|
|
62 |
C |
p. i
|
article
|
| 3 |
Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?
|
Regan, Meredith M.
|
|
|
62 |
C |
p. 179
|
article
|
| 4 |
Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data
|
Bernat-Peguera, Adrià
|
|
|
62 |
C |
p. 1-9
|
article
|
| 5 |
Essential amino acids deprivation is a potential strategy for breast cancer treatment
|
Zhao, Yajie
|
|
|
62 |
C |
p. 152-161
|
article
|
| 6 |
Evidence from a BreastScreen cohort does not support a longer inter-screen interval in women who have no conventional risk factors for breast cancer
|
Noguchi, Naomi
|
|
|
62 |
C |
p. 16-21
|
article
|
| 7 |
Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
|
Lee, Soohyeon
|
|
|
62 |
C |
p. 52-60
|
article
|
| 8 |
Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review
|
Yussof, Izzati
|
|
|
62 |
C |
p. 22-35
|
article
|
| 9 |
HER2 copy number quantification in primary tumor and cell-free DNA provides additional prognostic information in HER2 positive early breast cancer
|
Chen, Xiaobin
|
|
|
62 |
C |
p. 114-122
|
article
|
| 10 |
Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials
|
Zhang, Yi
|
|
|
62 |
C |
p. 162-169
|
article
|
| 11 |
Is breast conservation superior to mastectomy in early stage triple negative breast cancer?
|
Saifi, Omran
|
|
|
62 |
C |
p. 144-151
|
article
|
| 12 |
Moderately hypofractionated post-operative radiation therapy for breast cancer: Systematic review and meta-analysis of randomized clinical trials
|
Marta, Gustavo Nader
|
|
|
62 |
C |
p. 84-92
|
article
|
| 13 |
Neuroinflammation as potential precursor of leukoencephalopathy in early-stage breast cancer patients: A cross-sectional PET-MRI study
|
Schroyen, Gwen
|
|
|
62 |
C |
p. 61-68
|
article
|
| 14 |
Obstetric complications at time of delivery amongst breast cancer survivors: A population-based cohort study
|
Kaidar-Person, Orit
|
|
|
62 |
C |
p. 170-178
|
article
|
| 15 |
On top of that all, now Covid-19, too. A scoping review of specificities and correlates of fear of cancer recurrence in breast cancer patients during COVID-19
|
Kállay, Éva
|
|
|
62 |
C |
p. 123-134
|
article
|
| 16 |
Optimal localization strategies for non-palpable breast cancers –A network meta-analysis of randomized controlled trials
|
Davey, Matthew G.
|
|
|
62 |
C |
p. 103-113
|
article
|
| 17 |
Psychoeducation for breast cancer: A systematic review and meta-analysis
|
Setyowibowo, Hari
|
|
|
62 |
C |
p. 36-51
|
article
|
| 18 |
Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study
|
Cardoso Borges, Fábio
|
|
|
62 |
C |
p. 135-143
|
article
|
| 19 |
Response to: Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?
|
Ismail, R.K.
|
|
|
62 |
C |
p. 180
|
article
|
| 20 |
RE: The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa
|
Mansani, Fabio Postiglione
|
|
|
62 |
C |
p. 181
|
article
|
| 21 |
Retrospective literature review of primary neuroendocrine neoplasms of the breast (BNEN) in 209 Chinese patients: Treatment and prognostic factor analysis
|
Chai, Yue
|
|
|
62 |
C |
p. 93-102
|
article
|
| 22 |
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial
|
Cottu, Paul
|
|
|
62 |
C |
p. 75-83
|
article
|
| 23 |
Safety of pre- or postoperative accelerated radiotherapy in 5 fractions: A randomized pilot trial
|
Vakaet, Vincent
|
|
|
62 |
C |
p. 10-15
|
article
|
Journal description